{
    "guideline_id": "2024CSCO前列腺癌诊疗指南.txt",
    "cancer_info": {
        "cancer_name": "Prostate Cancer"
    },
    "clinical_recommendations": [
        {
            "clinical_context": "Screening for general population",
            "recommendation_type": "Diagnosis",
            "recommendation_content": "PSA testing for men ≥50 years with risk/benefit discussion",
            "treatment_line": "",
            "biomarker_requirements": [
                {
                    "biomarker_name": "PSA",
                    "status": "Not specified",
                    "testing_guidance": "Baseline and periodic testing; PSA progression defined as ≥25% increase from nadir and absolute value ≥2 ng/mL, confirmed after 3 weeks"
                }
            ],
            "recommendation_level": "Level I",
            "evidence_level": "Evidence A"
        },
        {
            "clinical_context": "Screening for high-risk individuals",
            "recommendation_type": "Diagnosis",
            "recommendation_content": "PSA testing for BRCA2 mutation carriers ≥40 years",
            "treatment_line": "",
            "biomarker_requirements": [
                {
                    "biomarker_name": "BRCA2",
                    "status": "Mutation carrier",
                    "testing_guidance": "Germline testing recommended for genetic counseling and screening"
                }
            ],
            "recommendation_level": "Level I",
            "evidence_level": "Evidence A"
        },
        {
            "clinical_context": "Initial diagnosis biopsy",
            "recommendation_type": "Diagnosis",
            "recommendation_content": "MRI fusion targeted biopsy combined with systematic biopsy (≥12 cores)",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "Level I",
            "evidence_level": "Evidence A"
        },
        {
            "clinical_context": "Localized prostate cancer - Very low or low risk",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Active surveillance or radical prostatectomy or radiotherapy",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I",
            "evidence_level": "Evidence A"
        },
        {
            "clinical_context": "Localized prostate cancer - Intermediate risk",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Radiotherapy + 6 months androgen deprivation therapy (ADT) or radical prostatectomy + pelvic lymph node dissection (for poor prognosis)",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I",
            "evidence_level": "Evidence A"
        },
        {
            "clinical_context": "Localized prostate cancer - High or very high risk",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Radiotherapy + 2-3 years ADT or radical prostatectomy + dissection; for very high risk, add abiraterone for 2 years",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I",
            "evidence_level": "Evidence A"
        },
        {
            "clinical_context": "Localized prostate cancer with regional lymph node metastasis",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Radiotherapy + 3 years ADT + abiraterone for 2 years",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I",
            "evidence_level": "Evidence B"
        },
        {
            "clinical_context": "Metastatic hormone-sensitive prostate cancer (mHSPC) - Low tumor burden",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "ADT + radiotherapy to primary site or ADT + novel endocrine therapy (abiraterone or enzalutamide)",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I",
            "evidence_level": "Evidence B (for ADT + radiotherapy) or Evidence A (for ADT + novel endocrine therapy)"
        },
        {
            "clinical_context": "Metastatic hormone-sensitive prostate cancer (mHSPC) - High tumor burden",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "ADT + docetaxel or ADT + abiraterone; no combined radiotherapy recommended",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I",
            "evidence_level": "Evidence A"
        },
        {
            "clinical_context": "Metastatic castration-resistant prostate cancer (mCRPC) - First-line treatment for HRR mutation positive",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Olaparib + abiraterone",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "HRR genes (e.g., BRCA1/2, ATM)",
                    "status": "Positive",
                    "testing_guidance": "Test for HRR mutations using germline and somatic testing; consistency >80% with ctDNA if tissue unavailable"
                }
            ],
            "recommendation_level": "Level I",
            "evidence_level": "Evidence A"
        },
        {
            "clinical_context": "Metastatic castration-resistant prostate cancer (mCRPC) - First-line treatment without chemotherapy history",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Enzalutamide or docetaxel; for oligometastasis: stereotactic body radiation therapy (SBRT) to metastases + abiraterone",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I",
            "evidence_level": "Evidence A (for enzalutamide/docetaxel) or Evidence III (for SBRT + abiraterone)"
        },
        {
            "clinical_context": "Metastatic castration-resistant prostate cancer (mCRPC) - Second-line treatment for PSMA positive",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "177Lu-PSMA-617",
            "treatment_line": "Second-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "PSMA",
                    "status": "Positive",
                    "testing_guidance": "Perform PSMA PET/CT for expression assessment"
                }
            ],
            "recommendation_level": "Level II",
            "evidence_level": "Evidence B"
        },
        {
            "clinical_context": "Metastatic castration-resistant prostate cancer (mCRPC) - Second-line treatment general",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Cabazitaxel (after docetaxel failure) or radium-223 (for bone metastasis)",
            "treatment_line": "Second-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I",
            "evidence_level": "Evidence B (for cabazitaxel) or Evidence A (for radium-223)"
        },
        {
            "clinical_context": "Neuroendocrine prostate cancer (NEPC)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Platinum-based chemotherapy (e.g., cisplatin/carboplatin) following small cell lung cancer regimens",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "Neuroendocrine markers (CGA, NSE, GRP)",
                    "status": "Elevated",
                    "testing_guidance": "Serum testing for diagnosis and monitoring; biopsy recommended for visceral metastasis or lytic bone lesions"
                }
            ],
            "recommendation_level": "Level I",
            "evidence_level": "Evidence A"
        },
        {
            "clinical_context": "Bone metastasis support",
            "recommendation_type": "Supportive Care",
            "recommendation_content": "Bone-protective agents: denosumab or zoledronic acid; monitor blood calcium, supplement calcium/vitamin D, and prevent osteonecrosis of the jaw",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "Level I",
            "evidence_level": "Evidence A"
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "HRR gene mutations (e.g., BRCA1/2, ATM) guide the use of PARP inhibitors like olaparib. PSMA expression predicts eligibility for 177Lu-PSMA therapy. Elevated neuroendocrine markers (CGA, NSE, GRP) indicate neuroendocrine prostate cancer and response to platinum-based chemotherapy. PSA progression (≥25% increase from nadir and ≥2 ng/mL) is a key diagnostic and monitoring criterion. CTC dynamics predict prognosis, with reduction to zero correlating with improved OS."
    },
    "tcm_recommendations": []
}